5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: A modeling analysis based on the CheckMate 9ER study
    Journal Article

    Cella, D.; Derosa, M.; Floden, L.; Giles, R. H.; Lothgren, M.; Ogareva, A.; Powles, T.; Purnajo, I.; Choueiri, T. K.; Bergerot, C.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma
    Journal Article

    Pal, S. K.; Bernard-Tessier, A.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; de Braud, F.; Takahashi, S.; Wong, A.; Suárez, C.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons
    Guidelines

    Grossman, R. L.; Vinson, J.; Bain, E.; Bisselou, K.; Chandan, S.; Compton, C.; Hu, J.; Johann, D. J.; Jones, F.; Jones, G.; more...
    CTS-Clinical and Translational Science (2025)

    Fulltext@MSK | Save
  • Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies
    Journal Article

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J.
    Cancers (2025)

    Fulltext@MSK | Save
  • High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes
    Journal Article

    Sharifi, M. N.; Sperger, J. M.; Taylor, A. K.; Tippins, K. E.; Reese, S. R.; Carreno, V.; Kaufmann, K. R.; Chang, A. H.; Nunamaker, L. A.; Linebarger, C.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301)
    Meeting Abstract

    Hansen, A. R.; Zhang, A. Y.; Boni, V.; Mantia, C.; Yu, E. Y.; Weickhardt, A. J.; Robert, M.; Gupta, S.; Morales-Barrera, R.; Hoimes, C. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Mak, B.; Tran, B.; Thomas, H.; Pashankar, F. D.; Hansen, A. R.; Feldman, D. R.; Huddart, R. A.; Wheater, M.; Dunwoodie, E.; Mazhar, D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors
    Meeting Abstract

    Gao, X.; Patnaik, A.; Lakhani, N. J.; Call, J. A.; Galsky, M. D.; Garmezy, B.; Wei, A. Z.; Carter, L.; Powles, T.; Siefker-Radtke, A. O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save